Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Catholic Medical Center
mi
from
Manchester, NH
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Catholic Medical Center
mi
from
Manchester, NH
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Cardiovascular Associates of the Delaware Valley, PA
mi
from
Haddon Heights, NJ
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Associates of the Delaware Valley, PA
mi
from
Haddon Heights, NJ
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Forsyth Medical Center
mi
from
Winston-Salem, NC
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Forsyth Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Oklahoma Heart Institute at Utica
mi
from
Tulsa, OK
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Oklahoma Heart Institute at Utica
mi
from
Tulsa, OK
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Lancaster General Hospital
mi
from
Lancaster, PA
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Lancaster General Hospital
mi
from
Lancaster, PA
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Donald Guthrie Foundation for Education and Research
mi
from
Sayre, PA
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Donald Guthrie Foundation for Education and Research
mi
from
Sayre, PA
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Greenville Health System
mi
from
Greenville, SC
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Greenville Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Erlanger Medical Center
mi
from
Chattanooga, TN
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Erlanger Medical Center
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Stern Cardiovascular Foundation
mi
from
Germantown, TN
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Stern Cardiovascular Foundation
mi
from
Germantown, TN
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
The Heart Hospital Baylor Plano
mi
from
Plano, TX
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
The Heart Hospital Baylor Plano
mi
from
Plano, TX
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center - Heart & Vascular
mi
from
Seattle, WA
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center - Heart & Vascular
mi
from
Seattle, WA
Click here to add this to my saved trials
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital
mi
from
Madison, WI
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease
Status: Enrolling
Updated:  12/31/1969
Alfieri Cardiology
mi
from
Wilmington, DE
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease
Status: Enrolling
Updated: 12/31/1969
Alfieri Cardiology
mi
from
Wilmington, DE
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Indianapolis, IN
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Algiers,
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Algiers,
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Chicago, IL
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Kansas City, KA
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jackson, MS
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Stony Brook, NY
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
Global Non-interventional Heart Failure Disease Registry
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
mi
from
Tampa, FL
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Ellipsis Group
mi
from
Atlanta, GA
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Ellipsis Group
mi
from
Atlanta, GA
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Hospital Universitario Austral
mi
from
Buenos Aires,
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Hospital Universitario Austral
mi
from
Buenos Aires,
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Cardiovascular Innovation and Research Center
mi
from
Long Beach, CA
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Innovation and Research Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Health and Life Research Institute, LLC
mi
from
Miami, FL
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Health and Life Research Institute, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Med-Care Research
mi
from
Miami, FL
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Med-Care Research
mi
from
Miami, FL
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Pines Care Research Center, LLC
mi
from
Pembroke Pines, FL
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Pines Care Research Center, LLC
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Wellstar Cardiovascular Medicine
mi
from
Marietta, GA
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Wellstar Cardiovascular Medicine
mi
from
Marietta, GA
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Fox Valley Clinical Research Center, LLC
mi
from
Aurora, IL
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Fox Valley Clinical Research Center, LLC
mi
from
Aurora, IL
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Sanford Cardiology
mi
from
Sanford, NC
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Sanford Cardiology
mi
from
Sanford, NC
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Lycoming Internal medicine
mi
from
Jersey Shore, PA
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Lycoming Internal medicine
mi
from
Jersey Shore, PA
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Research Associates of Jackson
mi
from
Jackson, TN
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Research Associates of Jackson
mi
from
Jackson, TN
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Cardiology Center of Houston
mi
from
Katy, TX
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Cardiology Center of Houston
mi
from
Katy, TX
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Cardio Voyage
mi
from
McKinney, TX
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Cardio Voyage
mi
from
McKinney, TX
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Waukesha Heart Institute
mi
from
Waukesha, WI
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Waukesha Heart Institute
mi
from
Waukesha, WI
Click here to add this to my saved trials
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated:  12/31/1969
Vidant Multispecialty Clnc Kinston
mi
from
Kinston, NC
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status: Enrolling
Updated: 12/31/1969
Vidant Multispecialty Clnc Kinston
mi
from
Kinston, NC
Click here to add this to my saved trials
CER-001 Atherosclerosis Regression ACS Trial
CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Heart Center Research, Llc
mi
from
Huntsville, AL
CER-001 Atherosclerosis Regression ACS Trial
CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Heart Center Research, Llc
mi
from
Huntsville, AL
Click here to add this to my saved trials